A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

BACKGROUND: Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib and IFN-α in patients with BRAFV600E melanoma may provide therapeutic benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Simeone, Ester, Scognamiglio, Giosuè, Capone, Mariaelena, Giannarelli, Diana, Grimaldi, Antonio M., Mallardo, Domenico, Madonna, Gabriele, Curvietto, Marcello, Esposito, Assunta, Sandomenico, Fabio, Sabbatino, Francesco, Bayless, Nicholas L., Warren, Sarah, Ong, SuFey, Botti, Gerardo, Flaherty, Keith T., Ferrone, Soldano, Ascierto, Paolo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789377/
https://www.ncbi.nlm.nih.gov/pubmed/33407577
http://dx.doi.org/10.1186/s12967-020-02680-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789377/
https://www.ncbi.nlm.nih.gov/pubmed/33407577
http://dx.doi.org/10.1186/s12967-020-02680-7

Ejemplares similares